Toll-Like Receptor 9 Is Required for Opioid-Induced Microglia Apoptosis

Lei He1,2*, Hui Li3, Lin Chen2,3*, Junying Miao4, Yulin Jiang5, Yi Zhang2, Zuoxiang Xiao6, Gregory Hanley7, Yi Li1, Xiumei Zhang3, Gene LeSage2*, Ying Peng1*, Deling Yin2*

1 Department of Neurology, Sun Yat-sen Memorial Hospital, Sun Yat-sen University, Guangzhou, People’s Republic of China, 2 Department of Internal Medicine, College of Medicine, East Tennessee State University, Johnson City, Tennessee, United States of America, 3 Department of Pharmacology, Shandong University School of Medicine, Jinan, People’s Republic of China, 4 Institute of Developmental Biology, Shandong University School of Life Science, Jinan, People’s Republic of China, 5 Department of Chemistry, East Tennessee State University, Johnson City, Tennessee, United States of America, 6 Cancer and Inflammation Program, Center for Cancer Research, National Cancer Institute at Frederick, Maryland, United States of America, 7 Division of Laboratory Animal Resources, College of Medicine, East Tennessee State University, Johnson City, Tennessee, United States of America

Abstract

Opioids have been widely applied in clinics as one of the most potent pain relievers for centuries, but their abuse has deleterious physiological effects beyond addiction. However, the underlying mechanism by which microglia in response to opioids remains largely unknown. Here we show that morphine induces the expression of Toll-like receptor 9 (TLR9), a key mediator of innate immunity and inflammation. Interestingly, TLR9 deficiency significantly inhibited morphine-induced apoptosis in microglia. Similar results were obtained when endogenous TLR9 expression was suppressed by the TLR9 inhibitor CpGODN. Inhibition of p38 MAPK by its specific inhibitor SB203580 attenuated morphine-induced microglia apoptosis in wild type microglia. Morphine caused a dramatic decrease in Bcl-2 level but increase in Bax level in wild type microglia, but not in TLR9 deficient microglia. In addition, morphine treatment failed to induce an increased levels of phosphorylated p38 MAPK and MAP kinase kinase 3/6 (MKK3/6), the upstream MAPK kinase of p38 MAPK, in either TLR9 deficient or μ-opioid receptor (μOR) deficient primary microglia, suggesting an involvement of MAPK and μOR in morphine-mediated TLR9 signaling. Moreover, morphine-induced TLR9 expression and microglia apoptosis appears to require μOR. Collectively, these results reveal that opioids prime microglia to undergo apoptosis through TLR9 and μOR as well. Taken together, our data suggest that inhibition of TLR9 and/or blockage of μOR is capable of preventing opioid-induced brain damage.

Introduction

Opioids have been used as potent analgesics for centuries; however, their abuse has deleterious physiological effects beyond addiction [1–3]. For example, they can somehow alter the functions of the immune and nervous systems [1,4,5]. Because opioid addicts are susceptible to certain infections, opioids such as morphine, have been suspected to suppress the immune response. This was supported by findings that various immune-competent cells express opioid receptors and undergo apoptosis when treated with opioid alkaloids [1–3,5–6]. Our previous studies revealed that chronic morphine exposure, such as occurs in drug abuse, promotes apoptosis both in vitro and in vivo [1,3,7–9]. In the central nervous system (CNS), we and others have previously reported that the importance of opioid-induced apoptosis in neurons [7,10]. Opioid receptors play critical roles in the processes of opioid-induced effects. All three opioid receptor types, μ, δ, and κ have been identified on microglia [4,11].

Microglia are key players of the immune response in the CNS and represent the resident immune host defense and are considered the major immune inflammatory cells of the CNS [12,13]. We and others have shown that morphine treatment-induced microglia apoptosis could be blocked by naloxone or naltrexone, specific opioid receptor antagonists, indicating a pivotal role of opioid receptors in this process [4,14]. Our recent studies found that a deficiency of Toll-like receptor 2 (TLR2) significantly inhibits morphine-induced apoptosis in primary neurons [15].

TLRs are well known for recognition of pathogens in the innate immune system aimed at defending the survival of the host [16–18]. To date, the TLR family includes a total of 13 receptors that are responsible for the recognition of highly conserved structural motifs that are essential for pathogen survival and are conserved across broad subclasses of microorganism [17,19,20]. Each TLR family member, with the exception of TLR3, signals through the MyD88 dependent pathway [17]. TLRs and their functions have been established in immune cells [17,18]. TLR3, TLR7, and
TLR9 are distinct from other TLRs in that they are not expressed on the plasma membrane [19,21]. TLR9 was identified as a key immune receptor in TLRs family that can recognize bacterial DNA as well as oligodeoxynucleotides (ODN) containing the CpG motifs responsible for the activating capacity of bacterial DNA (CpG s-ODN) [21,22]. Activation of TLR9 signaling triggers activation of proapoptotic signals, and causes cell apoptosis in various systems [19,21]. Growing evidence suggest that TLRs, including TLR9, expressed by microglial cells are critical in identifying and generating innate immune responses against bacterial and viral pathogens in the CNS [23–25]. Recently, it has been shown that TLR9, but not TLR2 or TLR4, plays a role in morphine inhibition of S.pneumoniae-induced NF-kB activity in the early stage of infection [26]. We have recently shown that morphine through potent stimulus of TLR9 caused altered host resistance against Mycobacterium tuberculosis in the lung of mouse model [19]. However, the role of TLR9 signaling on opioid-mediated apoptosis remains unknown.

One of three major subfamilies of mitogen-activated protein kinases (MAPKs) p38 MAPK plays a pro-apoptotic role [4,27,28]. Chronic morphine administration enhances the phosphorylation of p38 MAPK in dorsal root ganglion neurons [29]. Inhibition of p38 MAPK by p38 inhibitor SB203580 significantly attenuated tolerance to morphine analgesia [30]. P38 MAPK seems to sensitize cells to apoptosis by up-regulating Bax [31,32], a pro-apoptotic member of the Bcl-2 family [31,32]. The role of TLR9 in p38 MAPK and Bcl-2-mediated microglia apoptosis is not known yet. The objective of this study was to investigate the mechanisms by which opioids prime TLR9-mediated microglia apoptosis. Specifically we determined the involvement of μOR-mediated pro-apoptotic p38 MAPK and the upstream MAPK kinase (MKK3/6) of p38 MAPK, and Bcl-2 pathways. Here, we show that TLR9 is required for morphine-induced microglia apoptosis through p38 MAPK signaling pathway. Moreover, morphine promotes primary microglia apoptosis in a μ opioid receptor (μOR) dependent mechanism. Our studies thus provide an important insight into the mechanism of microglia apoptosis in response to opioids.

Results

Increased TLR9 expression in wild type microglia following morphine treatment

Although recent studies have demonstrated that TLR9 is expressed on microglia, the molecular mechanisms by which opioids affect microglia function in unknown [4,33]. To define the mechanisms, we treated primary mouse microglia from wild type mice with various concentrations of morphine for different time periods and examined the expression of TLR9 by quantitative real time RT-PCR and Western blot analysis. TLR9 expression in mRNA level was significantly increased following morphine treatment (Fig. 1A). Morphine-induced TLR9 expression was also detected at the protein level (Fig. 1B). The results demonstrated that morphine induces TLR9 expression in primary microglia in a dose and time dependent manner.

TLR9 deficiency prevents morphine-induced microglia apoptosis

We have recently reported that morphine promotes apoptosis in microglia [4]. To investigate whether TLR9 plays a role in opioid-induced microglia apoptosis, we treated primary mouse microglia from TLR9 knockout mice and wild type mice with morphine. The results showed that morphine-induced apoptosis was significantly reduced in TLR9 knockout mice compared to wild type mice. The results suggest that TLR9 is required for morphine-induced microglia apoptosis.

Figure 1. Morphine induces TLR9 expression in a dose and time dependent manner in wild type microglia. (A). Morphine induces the expression of TLR9 in mRNA level in a dose and time dependent. Mouse primary microglial cells were treated with 10 μM morphine for various time periods or different concentrations of morphine for 12 hr, respectively. The expression of TLR9 was determined by quantitative real time RT-PCR as described under Materials and Methods. Results represent mean ± SD of three independent experiments. (B). TLR9 expression in protein levels were determined by western blot. Cells were treated with 10 μM morphine for various time or various concentrations of morphine for 24 hr, respectively. Data are representative of three independent experiments.

doi:10.1371/journal.pone.0018190.g001
10 μM morphine for 24 h and evaluated cell apoptosis by TUNEL assay [4,15,19]. As shown in Fig. 2, a significant number of cells in the wild type microglia following morphine treatment were undergoing apoptosis, whereas only a few apoptotic cells were detected in the TLR9 deficient microglia after morphine treatment. Therefore, our results suggest TLR9 is required in opioid-mediated apoptosis in primary microglia.

Blockade of TLR9 attenuates morphine-induced microglia apoptosis

Because TLR9 deficiency inhibited morphine-induced apoptosis, we postulated that TLR9 blockade might protect wild type microglia following morphine treatment. We pretreated wild type primary microglia cells for 1 hr with the TLR9 inhibitor CpGODN2088 [34] or vehicle, and then treated with morphine for 24 hr. Apoptotic cells were analyzed either by TUNEL assay (Fig. 3A) or by flow cytometric analysis (Fig. 3B). We showed that co-exposure of wild type microglia to CpGODN2088 and morphine resulted in a significant decrease in apoptosis compared to cells treated with morphine alone (Fig. 3), suggesting that this approach may be useful clinically.

Inhibition of p38 MAPK diminishes morphine-induced microglia apoptosis

Opioids promote macrophage apoptosis through p38 MAPK phosphorylation [35]. To determine the role of p38 MAPK on TLR9-mediated microglia apoptosis induced by morphine exposure, we pretreated wild type and TLR9 deficient primary microglial cells with the specific p38 MAPK inhibitor SB 203580 [4] and then treated the cells in the presence or absence of morphine. We determined cell apoptosis by either TUNEL assay (Fig. 4A) or flow cytometry (Fig. 4B). As shown in Fig. 4, inhibition of p38 MAPK by SB203580 significantly attenuated morphine-induced apoptosis in wild type primary microglial cells. SB203580 did not alter the effects of morphine on TLR9 deficient microglial cells. SB203580 alone did not induce apoptosis in either wild type or TLR9 deficient microglial cells.

Inhibition of p38 MAPK attenuates morphine-induced alteration of Bcl-2 and Bax expression

It has been reported that p38 MAPK modulates Bcl-2/Bax-mediated apoptosis in neuroblastoma cells [32,36]. Our previous studies have reported that treatment of morphine with R37Ra protein significantly decreased the level of Bcl-2 and increased the level of Bax in the lung from wild type mice [19]. To examine whether p38 MAPK modulates Bcl-2 signaling following morphine treatment in TLR9-mediated signaling, we examined the expression of anti-apoptotic Bcl-2 and pro-apoptotic Bax by Western blot. Primary wild type microglia and TLR9 deficient microglial cells were treated with SB203580 for 1 hr and then treated with or without morphine for 24 hr. Morphine treatment significantly enhanced the expression of Bax but decreased Bcl-2 expression in wild type microglial cells (Fig. 5). In contrast, morphine did not alter the levels of Bcl-2 and Bax in the microglia from TLR9 knockout mice, suggesting that Bcl-2 family participates in TLR9-mediated microglia signaling following morphine treatment. Intriguingly, inhibition of p38 MAPK by SB203580 significantly diminished morphine-induced changes of Bcl-2 and Bax compared with the morphine treatment alone in wild type microglial cells, but not in TLR9 deficient microglial cells. SB203580 alone did not alter the level of Bax (Fig. 5). Thus, our data suggest that TLR9 plays a critical role in p38 MAPK-mediated Bcl-2 signaling in microglial cells following morphine treatment.

Effect of TLR9 and μOR on the levels of phosphor-p38 MAPK and phosphor-MKK3/6 following morphine treatment

Since inhibition of p38 MAPK could effectively block the morphine-induced apoptosis in wild type microglial cells (Fig. 4), its consequence on the level of phosphorylation of p38 MAPK was next determined in wild type and TLR9 deficient microglial cells with 10 μM morphine treatment for 24 hr. As shown in Fig. 6A, morphine significantly enhanced the level of phospho-p38 MAPK in wild type microglial cells. The increase of phospho-p38 in wild type microglial cells was attenuated markedly in TLR9 deficient primary microglia. We have shown that morphine induces microglia apoptosis through opioid-receptors [4]. To examine the role of μOR, a key opioid receptor of opioids’ actions, we determined the level of phospho-p38 MAPK in μOR deficient microglial cells following morphine treatment. We found that a deficiency of μOR in primary microglia strongly suppressed the level of P38 phosphorylation compared with wild type primary microglia following morphine treatment (Fig. 6A).

Next, we examine the of phosphorylation level of MKK3/6, the upstream MAPK kinase of p38 MAPK, in microglial cells with
10 μM morphine treatment for 24 hr. Morphine treatment resulted in a dramatic increase of MKK3/6 phosphorylation level in wild type primary microglia, but not in TLR9 or mOR deficient primary microglia (Fig. 6B). Taken together, these results suggest that p38 MAPK and MKK3/6 are involved in morphine-mediated microglia apoptosis through TLR9 and/or mOR.

**Morphine induces microglia apoptosis through μOR**

It has been established that several opioid receptor isoforms, including μOR, are expressed on microglia [11]. To test whether morphine-induced TLR9 is through μOR, we treated primary microglia from μOR knockout mice and from wild type mice with morphine at 10 μM and examined the expression of TLR9 by quantitative real time RT-PCR and immunohistochemistry. The expression of TLR9 was significantly induced by morphine in wild type microglia (data not shown), consistent with the findings of our results in Figure 1. Importantly, morphine could not alter the expression of TLR9 in μOR knockout microglia both in mRNA level (Fig. 7A) and protein level (data not shown). Taken together, our results demonstrated that morphine treatment significantly increases TLR9 expression through μOR.
We next investigated the role of opioid receptors, including μOR, in morphine-induced microglia apoptosis. Primary wild type microglial cells were exposed to morphine at 10 μM in the presence or absence of the opioid-receptor antagonist naloxone [4,9,37]. Apoptotic cells were examined either by TUNEL assay (Fig. 7B) or by flow cytometric analysis (Fig. 7C). We observed that pretreatment with naloxone dramatically blocked morphine-induced microglia apoptosis (Figs. 7B and 7C). Treatment of microglia with naloxone alone did not alter the percentage of apoptosis (data not shown). We next tested with a specific μOR agonist [D-Ala2, N-MePhe4, Gly-ol]-enkephalin (DAMGO). DAMGO significantly induced microglia apoptosis but no significant difference was observed when compared with the morphine treatment group (Figs. 7B and 7C). Morphine could not cause apoptosis in μOR deficient microglia (data not shown). Therefore, morphine-induced microglia apoptosis appears to require μOR.

**Discussion**

The data presented herein revealed for the first time, to our best knowledge, a key role for microglia TLR9 in the induction of morphine-mediated apoptosis. Our studies demonstrate that
Opioids-Induced Apoptosis via TLR9

Morphine treatment modulates TLR9 signaling and results in microglia apoptosis. It is widely accepted that TLR9 signaling mainly activates inflammatory responses, including proinflammatory cytokines [18,21,22,38]. Many studies focused attention on TLR9-mediated apoptosis in immune system [18,21]. Recent studies have shown that apoptosis via TLR9 on immune cells may play a role in the pathogenesis of various autoimmune diseases [39]. In this study, we identify that deficiency of TLR9 activity in primary microglia blocked morphine-induced microglial apoptosis. Morphine concentration we used in this study is physiologically relevant and these levels can be achieved in the brains of patients given opioids [4,14,40,41]. Our studies revealed that TLR9 signaling is activated by opioids in microglia without the presence of immune cells. We discovered that the absence of TLR9 blocked microglia apoptosis induced by morphine treatment (Fig. 2). Importantly, these features in TLR9 deficient microglia were replicated in wild type microglia through the administration of the TLR9 inhibitor ODN2088 (Fig. 3). Thus, our results demonstrate that Bcl-2 and Bax participate in TLR9-mediated microglia apoptosis. Taken together, our studies found that morphine significantly decreased the levels of Bcl-2 and increased the levels of Bax in the microglia from wild type mice. Interestingly, inhibition of p38 MAPK attenuated morphine-induced the alterations of Bcl-2 and Bax expression (Fig. 5). However, morphine did not alter the levels of Bcl-2 and Bax in the microglia from TLR9 knockout mice. Taken together, our studies demonstrate that Bcl-2 and Bax participate in TLR9-mediated p38 MAPK signaling in morphine-induced apoptosis in microglia.

Previous in vitro studies have demonstrated that morphine and DAMGO, a specific µ-opioid receptor agonist, induce apoptosis in lymphocytes [44]. Our results showed that morphine induces microglia apoptosis through a µOR dependent mechanism (Fig. 7). To discriminate between the eventual effect of morphine on TLR9 and µOR, we have made a novel observation that morphine could not induce TLR9 expression in primary µOR deficient microglia in both mRNA and protein levels. Therefore, the regulation of TLR9 by morphine described here is µOR dependent. However, it is unclear how up-regulation of TLR9 leads to apoptosis induced by either morphine or DAMGO. The mechanisms by which morphine as well as DAMGO leads the up-regulation of TLR9 to microglia apoptosis will be investigated in future studies. It has been recently reported that opioids induce glial action not though classical opioid receptors, but rather through non-stereoselective activation of TLR4 [45]. However, the role of non-stereoselective TLR4-mediated signaling remains under investigation [45]. To our best knowledge, we provided the fist evidence that morphine induces TLR9 expression through a classical µOR dependent mechanism. Further investigations should be performed to understand the mechanisms on TLR9 regulation by morphine via µOR.

Materials and Methods

Experimental animals

TLR9 knockout (TLR9 KO) mice were kindly provided by Dr. Shizuo Akira, Osaka University, Osaka, Japan via Dr. Dennis Klinman, National Cancer Institute, Frederick, MD [19]. Mu-opioid receptor KO mice were kindly provided by Dr. Srinivasa Raja, Johns Hopkins University School of Medicine, Baltimore, MD [8]. KO mice and wild type mice were maintained in the same room in the Division of Laboratory Animal Resources at East Tennessee State University (ETSU), a facility accredited by the Association for the Assessment and Accreditation of Laboratory Animal Care International (AAALAC). All aspects of the animal care and experimental protocols were approved by the ETSU Committee on Animal Care.

Reagents

Morphine sulfate and naloxone were obtained from Sigma-Aldrich (St. Louis, MO). Antibodies, including total and phospho-p38 and MKK3/6, were purchased from Cell Signaling Technology (Beverly, MA). TLR9 antibody was purchased from IMGENEX.
(San Diego, CA). The antibodies of GAPDH, Bax, and Bcl-2 were purchased from Santa Cruz Biotechnology (Santa Cruz, CA). P38 inhibitor SB203580 was obtained from Tocris Bioscience (Bristol, UK). TLR9 inhibitor ODN2088 was obtained from InvivoGen (San Diego, CA).

**Primary microglial cells culture**

Mouse primary microglial cells were isolated from mixed glial cultures, as described in our previous studies [4,46]. Briefly, primary mixed glial cultures were prepared from postnatal day 1–2 mice. Primary microglia were co-cultured with astrocytes in
poly-D-lysine-coated 75-cm² culture flasks in DMEM (Gibco BRL, Gaithersburg, MD) supplemented with 10% heat-inactivated fetal bovine serum (FBS) (Atlanta Biologicals, Lawrenceville, GA) and 1% Penicillin/Streptomycin. On days 10–14, microglial cells were harvested by shaking the cultures (180 rpm) and collecting the floating cells. These cells were seeded into plastic tissue culture flasks. After incubation at 37°C for 1 h, non-adherent cells were removed by replacing culture medium. The cells were grown in DMEM with 10% FBS and maintained at 37°C and 5% CO₂. The purity of microglia was verified >95% by ricinus communis agglutinin-1 (RCA-1, a microglia marker) immunostaining.

Figure 7. Morphine induces microglia apoptosis in a μOR dependent manner. (A) Morphine could not induce the expression of TLR9 in μOR KO microglia. μOR deficient microglia cells were treated morphine at 10 μM for 12 hr and the expression of TLR9 in mRNA levels determined by quantitative real time RT-PCR as in Fig. 1A. Wild type microglial cells were treated with 10 μM morphine with or without 20 μM naloxone pretreatment. Another group of cells were treated with 10 μM DAMGO alone for 24 hr. Apoptotic cells were examined as in Fig. 3. (B). Representative light microscopic images showed TUNEL-positive microglia (red arrow head). Magnification 200×. Results represent mean ± SD from three independent experiments. * p<0.01 compared with indicated groups. (C). Apoptotic cells were analyzed by flow cytometry. These results are representative of three independent experiments. 

doi:10.1371/journal.pone.0018190.g007
Western blot analysis

Western blot was performed as described previously in our published work [3,46,47]. Briefly, the cellular proteins were separated by SDS-polyacrylamide gel electrophoresis and transferred onto Hybond ECL membranes (Amersham Pharmacia, Piscataway, NJ). The membrane was then incubated at room temperature in a blocking solution composed of 5% skim milk powder dissolved in 1× TBS for 1 h. The membrane was then incubated with the blocking solution containing the first antibody overnight at 4°C. After washing three times with TBS for 5 min, the blot was then incubated with a second antibody. The blot was again washed three times with TBS before being exposed to the SuperSignal West Dura Extended Duration substrate (Pierce Biotechnology, Rockford, IL). Band intensity was quantified by densitometric analyses using a densitometer.

Quantification of apoptosis by TUNEL assay

The experimental cells were treated with different concentrations of morphine in the presence or absence of SB203580 for 24 h or ODN2088 for 1 h. Apoptotic cells were determined by terminal deoxynucleotidyl transferase biotin-d UTP nick end labeling (TUNEL) assay using a situ cell death detection kit (Roche Diagnostic, Indianapolis, IN) according to the manufacturer’s instruction as described in our previous studies [19,37,47]. The percentage of apoptotic cells was calculated by counting approximately 500 cells.

Flow cytometry

Apoptotic cells were examined by flow cytometry as described previously [1,37,48]. Briefly, cells (1×10⁶) were washed twice with cold PBS and then suspended cells in 200 μL of 1X binding buffer and 5 μL of fluorescein isothiocyanate (FITC)-labeled Annexin V (R&D Systems, Minneapolis, MN) for 20 minutes in the dark, and thereafter 300 μL of 1X binding buffer and 5 μL of propidium iodide (Sigma, St. Louis, MO) were added to each sample. After incubation at RT (25°C) for 10 min in the dark, the cells were analyzed for apoptosis on a FACScan flow cytometer with CellQuest software (Becton Dickinson). All data are representative of three independent experiments.

Real-time quantitative RT-PCR

Total RNA was isolated from lungs by the VERSA GENETM RNA Tissue Kit (Genta SYSTEMS; Minnesota) and the real-time RT-PCR detection technique was performed as described in our previous publications [15,19]. Briefly, first-strand cDNA was synthesized from 1 μg of total RNA using a Reaction Ready™ first strand cDNA synthesis kit (SA Biosciences, Frederick, MD). cDNA was subjected to real-time quantitative PCR using Bio-Rad iQ Multicolor Real-Time PCR Detection System (Bio-Rad Life Science Research, Hercules, CA). TLR9 primer pairs were used: CTCCTGTTGTGGAAACATCAT (forward) and GTTGGGAGGTTGGACGGAAGT (reverse). PCR assay was performed in triplicate. The reaction conditions were: 50°C for 2 min, 95°C for 8 min 30 s, followed by 27 cycles of 95°C for 15 s, 60°C for 60 s, and 72°C for 30 s.

Statistical analysis

Results were expressed as mean ± SD. Statistical significance was assessed by one-way analysis of variance (ANOVA) and the student’s test. Prism 5.0 (GraphPad Software, San Diego, CA) was used for all calculations. A value of p<0.05 was considered statistically significant.

Acknowledgments

The authors wish to express their appreciation to Dr. Shizuo Akira, Osaka University, Osaka, Japan and Dr. Dennis Kliman, National Cancer Institute, Frederick of MD, for providing TLR9 knockout mice and to Dr. Srinivas Raja, Johns Hopkins University School of Medicine, for providing mu-opioid receptor knockout mice.

Author Contributions

Conceived and designed the experiments: LH HL LC YZ YL ZX GH YL XZ YP DY. Performed the experiments: LH HL LC YZ YL. Analyzed the data: LH HL LC YP DY. Contributed reagents/materials/analysis tools: LH HL LC YP DY. Wrote the paper: LH HL LC GH YL YP DY.
pathway in human chronic lymphocytic leukemia B cells. Blood 115: 5041–5052.
22. Sasai M, Linehan M, Iwasaki A (2010) Bifurcation of Toll-like receptor 9 signaling by adaptor protein 3. Science 329: 1530–1534.
23. Kim D, Kim M, Cho I, Kim M, Lee S, et al. (2007) A critical role of toll-like receptor 2 in nerve injury-induced spinal cord glial cell activation and pain hypersensitivity. J Biol Chem 282: 14973–14983.
24. Lehnardt S, Henneke P, Lien E, Kasper D, Volpe J, et al. (2006) A mechanism for neurodegeneration induced by group B streptococci through activation of the TLR2/MyD88 pathway in microglia. J Immunol 177: 583–592.
25. Zhou S, Halle A, Kurt-Jones E, Cerny A, Porpiglia E, et al. (2008) Lymphocytic Choriomeningitis Virus (LCMV) infection of CNS glial cells results in TLR3-Mediated inflammatory responses. J Neuroimmunol 194: 76–82.
26. Wang J, Barke R, Charboneau R, Schwendener R, Roy S (2008) Morphine Induces Defects in Early Response of Alveolar Macrophages to Streptococcus pneumoniae by Modulating Toll-RII-NF-(kappa)-B Signaling. J Immunol 180: 3594–3600.
27. Chang L, Karin M (2001) Mammalian MAP kinase signalling cascades. Nature 410: 37–40.
28. Ichijo H (1999) From receptors to stress-activated MAP kinases. Oncogene 18: 6087–6093.
29. Ma W, Zheng W, Powell K, Jhamandas K, Quirion R (2001) Chronic morphine tolerance. Brain Res 1069: 235–243.
30. Nelyudova A, Aksenov N, Pospelov V, Pospelova T (2007) By blocking activation of p38 mitogen-activated protein kinase in spinal microglia mediates morphine antinociceptive tolerance. Brain Res 1069: 235–243.
31. Porras A, Zuba Saq A, Black E, Valladares A, Alvarez A, et al. (2004) P38 alpha mitogen-activated protein kinase sensitizes cells to apoptosis induced by different stimuli. Mol Biol Cell 15: 922–933.
32. Chang C, Tsai W, Chuang W, Lin Y, Wu J, et al. (2009) Procaspase 8 and Bax are up-regulated by distinct pathways in Streptococcal pyrogenic exotoxin B-induced apoptosis. J Biol Chem 284: 33193–33205.
33. Essen N, Kielian T (2006) Central role for MyD88 in the responses of microglia to pathogen-associated molecular patterns. J Immunol 176: 6002–6011.
34. Bamboat Z, Balachandran V, Ocun I, Ohsaid H, Plitas G, et al. (2010) Toll-like receptor 9 inhibition confers protection from liver ischemia-reperfusion injury. Hepatology 51: 621–632.
35. Singhal P, Bhaskaran M, Patel J, Patel K, Kasinath B, et al. (2002) Role of p38 mitogen-activated protein kinase phosphorylation and Fas-Fas ligand interaction in morphine-induced macrophage apoptosis. J Immunol 168: 4025–4033.
36. Gomez-Lazaro M, Galindo M, Mezio-Fernandez de Mera RM, Fernandez-Gomez F, Concannon C, et al. (2007) Reactive oxygen species and p38 mitogen-activated protein kinase activate Bax to induce mitochondrial cytochrome c release and apoptosis in response to malonate. Mol Pharmacol 71: 736–743.
37. Yiu D, Tushill D, Mufson R, Shi Y (2000) Chronic restraint stress promotes lymphocyte apoptosis by modulating CD95 expression. J Exp Med 191: 1423–1428.
38. Zhu J, Huang X, Yang Y (2009) The TLR3-MyD88 pathway is critical for adaptive immune responses to adeno-associated virus gene therapy vectors in mice. J Clin Invest 119: 2398–2398.
39. Papadimitraki ED, Choulaki C, Koutala E, Bertsias G, Tsatsanis C, et al. (2006) Expansion of toll-like receptor 9-expressing B cells in active systemic lupus erythematosus: implications for the induction and maintenance of the autoimmune process. Arthritis Rheum 54: 3601–3611.
40. Zhang Y, Li H, Li Y, Sun X, Zhu M, et al. (2011) Essential role of toll-like receptor 2 in morphine-induced microglia activation in mice. Neurosci Lett 489: 43–47.
41. Bohin L, Gainetdinov R, Lin F, Leikowitz R, Caron M (2000) Mu-opioid receptor desensitization by beta-arrestin-2 determines morphine tolerance but not dependence. Nature 408: 720–723.
42. Nelyudova A, Aksenov N, Pospelov V, Pospelova T (2007) By blocking apoptosis, Bcl-2 in p38-dependent manner promotes cell cycle arrest and accelerated senescence after DNA damage and serum withdrawal. Cell Cycle 6: 2171–2177.
43. Singhal PG, Kapasi A, Reddy K, Franki N, Gibbons N, et al. (1999) Morphine promotes apoptosis in Jurkat cells. J Leukoc Biol 66: 650–658.
44. Boronat MA, Garcia Fuster M, Garcia-Segovia JA (2001) Chronic morphine induces up-regulation of the pro-apoptotic Fas receptor and down-regulation of the anti-apoptotic Bcl-2 oncoprotein in rat brain. Br J Pharmacol 134: 1263–1270.
45. Watkins LR, Hutchinson M, Rice K, Maier S (2009) The “toll” of opioid-induced glial activation: improving the clinical efficacy of opioids by targeting glia. Trends Pharmacol Sci 30: 581–591.
46. Xie N, Wang C, Lin Y, Li H, Chen L, et al. (2010) The role of p38 MAPK in valproic acid induced microglia apoptosis. Neurosci Lett 482: 51–56.
47. Li H, Sun X, LeSage G, Zhang Y, Liang Z, et al. (2010) Beta-Arrestin-2 regulates toll-like receptor 4-mediated apoptotic signalling through glycosyn thase kinase-3beta. Immunology 130: 556–563.
48. Tob ML, Gonzales G, Koeners M, Tsourmadie A, Boyle D, et al. (2010) Role of interleukin 17 in arthritis chronicity through survival of synoviocytes via regulation of synoviolin expression. PLoS One 5: e13416.